Jump to content

SLA - SILK LASER AUSTRALIA LIMITED


ShareCafe

Recommended Posts

  • Replies 43.2k
  • Created
  • Last Reply

Top Posters In This Topic

  • chiller

    2097

  • diana

    1910

  • Livas1

    4166

  • jezzabot

    2629

Top Posters In This Topic

Posted Images

Congratulations to Vagif and all the SLA team.

 

My shares are locked in a safe and are staying there.

 

Sandy and I are leaving next week for Europe.

 

Sorry to miss the Ropren party but hopefully we will be back for the AGM or EGM.

 

Congratulations to everybody who holds. Looks like we have the next few years mapped out.

 

Happy, Happy, happy.

Link to comment
Share on other sites

A whole new direction

 

 

"Registration opens the door for Solagran to begin to activate its global development strategy. When executed successfully, that strategy has the potential to create a whole new direction in medicine involving the use of highly effective but low side-effect natural Bioeffectives ÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚®."

 

http://www.sharescene.com/html/emoticons/graduated.gif

Link to comment
Share on other sites

18 July, 2007

Company Announcement

Pharmaceutical Registration of BioeffectiveÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® R and Ropren

The Directors of Solagran Limited are pleased to announce that the Company has received

formal documentation from the Russian Ministry of Heath advising that pharmaceutical

registration of both the substance BioeffectiveÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® R and the medicine Ropren has been

finalised.

The Directors regard this as a tremendous achievement after an intense four year effort.

Solagran is now free to promote Ropren in Russia as a highly effective treatment for chronic

liver disease.

Solagran will now focus on scaling up production facilities sufficient to meet the expected

demand in Russia. It can also now initiate the next stage of its Ropren strategy which is to

obtain pharmaceutical registration in the European Union as a precursor to taking it to North

America and Asia.

Strategy in Russia

Ropren is a unique natural medicine. Its active ingredient BioeffectiveÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® R is one of a family of

17 BioeffectivesÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® that SolagranÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s research team has developed over 30 years. Each has

multifaceted activity and few if any side effects.

Ropren has been approved in Russia as a strong and effective natural hepatoprotector.

Clinical trials have also demonstrated that Ropren has the potential to normalise lipid

metabolism, strengthen the immune system, prevent and treat neurodegenerative disorders,

and deal with conditions associated with drug and alcohol addiction.

The ability of Ropren to deal so effectively with chronic liver disease will have a very positive

social impact in Russia. There are more than 10 million people with liver disease in Russia

and the CIS countries, with up to 1 million new cases and 100,000 deaths each year.

Figure 1 illustrates SolagranÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¾Ãƒâہ¡ÃƒÆ’‚¢s expectations in relation to the demand for Ropren in Russia.

The Board expects demand for use in treating liver disease alone to reach 320,000 courses

in 2010 and exceed 1 million courses per year by 2012.

Initially, the market is expected to be supply constrained, with Solagran only having capacity

to meet the demand expected from hospitals and pharmacies in the cities of Moscow and St

Petersburg.

For personal use only

Link to comment
Share on other sites

Great news...

 

Congratulations to the team at Solagran and all loyal shareholders http://www.sharescene.com/html/emoticons/king.gifhttp://www.sharescene.com/html/emoticons/king.gifhttp://www.sharescene.com/html/emoticons/king.gif

Link to comment
Share on other sites

1,000,000+ Courses by 2012 * $3000 per course * 50% profit (lets be conservative) * PE of 20 gives Markey cap of 30,000,000,000. THATS RIGHT, a $30 BILLION Company, or SP of $100 fully diluted?

 

Correct me if I'm wrong but this is good. Very good.

 

 

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...